NasdaqGM - Delayed Quote USD

VanEck Pharmaceutical ETF (PPH)

85.14 +0.27 (+0.32%)
At close: 4:00 PM EDT
Loading Chart for PPH
DELL
  • Previous Close 84.87
  • Open 84.94
  • Bid 85.01 x 200
  • Ask 85.39 x 200
  • Day's Range 84.85 - 85.26
  • 52 Week Range 74.05 - 91.16
  • Volume 72,869
  • Avg. Volume 126,067
  • Net Assets 543.21M
  • NAV 84.86
  • PE Ratio (TTM) 20.57
  • Yield 1.87%
  • YTD Daily Total Return 4.94%
  • Beta (5Y Monthly) 0.60
  • Expense Ratio (net) 0.36%

The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

VanEck

Fund Family

Health

Fund Category

543.21M

Net Assets

2011-12-20

Inception Date

Performance Overview: PPH

Trailing returns as of 4/18/2024. Category is Health.

YTD Return

PPH
4.94%
Category
6.33%
 

1-Year Return

PPH
9.70%
Category
11.04%
 

3-Year Return

PPH
8.88%
Category
0.38%
 

People Also Watch

Holdings: PPH

Top 10 Holdings (63.83% of Total Assets)

SymbolCompany% Assets
LLY
Eli Lilly and Company 11.78%
NVO
Novo Nordisk A/S 9.44%
JNJ
Johnson & Johnson 6.68%
MRK
Merck & Co., Inc. 6.24%
ABBV
AbbVie Inc. 6.08%
AZN
AstraZeneca PLC 5.15%
NVS
Novartis AG 4.72%
COR
Cencora, Inc. 4.62%
MCK
McKesson Corporation 4.56%
PFE
Pfizer Inc. 4.55%

Sector Weightings

SectorPPH
Healthcare   100.00%
Real Estate   0.00%
Technology   0.00%
Utilities   0.00%
Industrials   0.00%
Energy   0.00%

Recent News: PPH

Research Reports: PPH

  • Analyst Report: Elevance Health, Inc.

    Elevance Health remains one of the leading health insurers in the U.S., providing medical benefits to 47 million medical members as of December 2023. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs such as Medicaid and Medicare Advantage plans, too.

    Rating
    Neutral
    Price Target
     
  • RMBS: Lowering target price to $62.00

    RAMBUS INC has an Investment Rating of HOLD; a target price of $62.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Neutral
    Price Target
     
  • RMBS: Raising target price to $65.00

    RAMBUS INC has an Investment Rating of HOLD; a target price of $65.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Neutral
    Price Target
     
  • VRSN: Raising target price to $201.00

    VERISIGN INC has an Investment Rating of HOLD; a target price of $201.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Neutral
    Price Target
     

Related Tickers